Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

In healthy volunteers, a monoclonal antibody fragment that binds ticagrelor and its active metabolite led to reversal of the antiplatelet effects of ticagrelor, with very few toxic effects. The presence of low titers of antibody to the active agent had no detectable effect on efficacy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-05, Vol.380 (19), p.1825-1833
Hauptverfasser:	Bhatt, Deepak L, Pollack, Charles V, Weitz, Jeffrey I, Jennings, Lisa K, Xu, Sherry, Arnold, Susan E, Umstead, Bret R, Mays, Michael C, Lee, John S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiplatelet therapy Aspirin Bleeding Blood platelets Cardiology Double-blind studies Drug dosages Intravenous administration Ischemia Monoclonal antibodies Myocardial infarction Pharmaceuticals Platelet aggregation Surgery Vasodilator-stimulated phosphoprotein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In healthy volunteers, a monoclonal antibody fragment that binds ticagrelor and its active metabolite led to reversal of the antiplatelet effects of ticagrelor, with very few toxic effects. The presence of low titers of antibody to the active agent had no detectable effect on efficacy.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1901778